drugset / Trial / NCT00735267
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMAGABALIN | Other / unclassified | 350 mg | Oral |
| Subject | IMAGABALIN | Other / unclassified | 600 mg | Oral |